Table 1.
Patient characteristics
| ≥20% ICI infusions prior to noon N=101 (%) |
<20% ICI infusions prior to noon N=100 (%) |
P value | |
| Sex | 0.10 | ||
| Female | 22 (22) | 33 (33) | |
| Male | 79 (78) | 67 (67) | |
| Age at ICI initiation | 0.08 | ||
| ≤50 | 16 (16) | 17 (17) | |
| 51–60 | 17 (17) | 32 (32) | |
| 61–70 | 42 (41) | 28 (28) | |
| 71–80 | 22 (22) | 17 (17) | |
| ≥81 | 4 (4) | 6 (6) | |
| ECOG | 0.86 | ||
| 0 | 45 (44) | 41 (41) | |
| 1 | 39 (39) | 40 (40) | |
| ≥2 | 17 (17) | 19 (19) | |
| Statin use | 34 (34) | 38 (38) | 0.62 |
| IMDC risk score | 0.37 | ||
| 0 (favorable) | 10 (10) | 7 (7) | |
| 1–2 (intermediate) | 55 (54) | 48 (48) | |
| ≥3 (poor) | 36 (36) | 45 (45) | |
| RCC histology | 0.74 | ||
| Clear cell | 74 (73) | 68 (68) | |
| Papillary | 5 (5) | 6 (6) | |
| Chromophobe | 2 (2) | 1 (1) | |
| Collecting duct | 3 (3) | 1 (1) | |
| Sarcomatoid | 1 (1) | 2 (2) | |
| Mixed histologies of the above | 7 (7) | 12 (12) | |
| With sarcomatoid features | 1 (1) | 3 (3) | |
| With chromophobe features | 0 (0) | 0 (0) | |
| Other (eg, eosinophilic, Xp11 translocation, poorly differentiated) | 9 (9) | 10 (10) | |
| Pretreatment LDH | 0.51 | ||
| Normal | 52 (51) | 54 (54) | |
| Elevated | 12 (12) | 16 (16) | |
| Unknown | 37 (37) | 30 (30) | |
| Bone metastasis | 34 (34) | 28 (28) | 0.48 |
| Brain metastasis | 9 (9) | 18 (18) | 0.09 |
| Liver metastasis | 28 (28) | 25 (25) | 0.78 |
| First-line therapy included ICI | 44 (44) | 32 (32) | 0.12 |
| Initial ICI regimen | 0.57 | ||
| Nivolumab | 43 (43) | 53 (53) | |
| Nivolumab+TKI | 11 (11) | 10 (10) | |
| Pembrolizumab | 3 (3) | 3 (3) | |
| Pembrolizumab+TKI | 4 (4) | 5 (5) | |
| Dual nivolumab/ipilimumab | 40 (40) | 29 (29) | |
| ICI ever received* | |||
| Nivolumab | 54 (53) | 63 (63) | 0.22 |
| Pembrolizumab | 14 (14) | 8 (8) | 0.27 |
| Dual nivolumab/ipilimumab | 40 (40) | 30 (40) | 0.20 |
| Non-ICI systemic therapies ever received* | |||
| Cabozantinib | 47 (46) | 39 (39) | 0.35 |
| Pazopanib | 29 (29) | 31 (31) | 0.84 |
| Sunitinib | 12 (12) | 22 (22) | 0.08 |
| Everolimus | 19 (19) | 13 (13) | 0.35 |
| Lenvatinib | 16 (16) | 6 (6) | 0.05 |
| Axitinib | 9 (9) | 7 (7) | 0.81 |
*Percentages do not add up to 100 because some patients received multiple ICI and non-ICI systemic therapy regimens.
ECOG, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium; LDH, lactate dehyrogenase; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.